VKORC1 Genetic Test: Warfarin Sensitivity, Dose, and Results

A VKORC1 genetic test examines inherited variation in the gene that makes warfarin’s molecular target. The result most often reported, VKORC1 c.-1639G>A (rs9923231), helps estimate whether a person is likely to need a lower, intermediate, or higher warfarin maintenance dose relative to others. It is most useful when warfarin is being started and the result is combined with CYP2C9 findings and clinical information in a validated dosing algorithm. The test does not produce a safe dose by itself, replace international normalized ratio (INR) monitoring, diagnose a bleeding disorder, or account for changing diet, illness, adherence, and interacting medicines. The genotype remains the same throughout life, but its practical value is greatest before enough INR and dose-response data have accumulated. Safe interpretation depends on knowing exactly which variant the laboratory tested and using the finding as one part of a complete anticoagulation plan.

• VKORC1 affects sensitivity at warfarin’s target, not the rate of warfarin clearance.
• A/A usually predicts greater sensitivity, G/A intermediate sensitivity, and G/G lower sensitivity, but these are average tendencies rather than fixed doses.
• Testing helps most near treatment initiation, particularly when CYP2C9 and appropriate clinical variables are available at the same time.
• INR monitoring remains mandatory because genetics cannot measure the anticoagulant effect occurring today.
• A common-variant test does not rule out rare VKORC1 changes that may contribute to unusual warfarin resistance.

Table of Contents

• What a VKORC1 Test Can—and Cannot—Tell You
• How VKORC1 Controls Warfarin Sensitivity
• Who May Benefit and When Testing Helps Most
• Sample Types, Methods, and Test Coverage
• How to Interpret VKORC1 Results
• How Clinicians Turn a Result Into a Dose Estimate
• INR Monitoring, Interactions, and Safety
• Limitations, Rare Resistance, and Next Steps

What a VKORC1 Test Can—and Cannot—Tell You

Warfarin has a narrow therapeutic range. Too little anticoagulation may leave a person vulnerable to a clot, while too much may cause serious bleeding. The dose needed to reach the same INR target differs widely among patients. VKORC1 testing addresses one important source of that variability: inherited differences in the amount of warfarin’s target in the vitamin K cycle.

Most clinical tests report the promoter variant c.-1639G>A, also called -1639G>A or rs9923231. The A allele is associated with lower VKORC1 expression. With less target protein available, a smaller amount of warfarin often produces the intended effect. The G allele is associated with higher expression and, on average, a higher dose requirement. This relationship shifts a dose estimate; it does not define a prescription.

A result may help a clinician judge whether a person is relatively sensitive to warfarin, whether an initial estimate should move lower or higher, and whether an unusually low early requirement has a plausible genetic contribution. It cannot reveal how quickly active warfarin is cleared, establish the correct INR target, diagnose active bleeding, confirm that a clot has resolved, or decide whether another anticoagulant is appropriate.

CYP2C9 is crucial because it contributes to clearance of the more potent S-warfarin enantiomer. Age, body size, liver function, illness, diet, alcohol exposure, adherence, and interacting medicines also influence response. A person can therefore have a high-sensitivity VKORC1 genotype yet require more warfarin than expected, or a lower-sensitivity genotype yet need a small dose.

Timing changes the value of the information. Before treatment, genotype can improve an initial estimate. After repeated therapeutic INRs establish a stable dose, the observed dose-response relationship usually supplies more direct evidence. The genetic result remains valid but adds less new information.

The result may still be useful later when records are incomplete, a patient transfers care, or clinicians need to explain why the established requirement is unusually low. It can also prevent future misinterpretation of a low dose as under-treatment when the INR is therapeutic. However, the established dose should not be recalculated solely because a delayed genetic report arrives. Clinicians should compare the predicted direction with the actual INR history, confirm that current dosing is stable, and avoid disrupting successful management without a clinical reason. This distinction between explanatory value and immediate dosing value is important whenever testing returns after therapy has begun.

A warfarin pharmacogenetic test generally evaluates VKORC1 with genes affecting metabolism and vitamin K handling. That multigene approach is more suitable for dose calculation than a stand-alone VKORC1 result.

How VKORC1 Controls Warfarin Sensitivity

VKORC1 encodes vitamin K epoxide reductase complex subunit 1. The enzyme recycles oxidized vitamin K into a form the liver can use. Reduced vitamin K is required to activate clotting factors II, VII, IX, and X and the natural anticoagulant proteins C and S.

Warfarin inhibits VKORC1. As usable vitamin K declines, the liver produces fewer fully active vitamin K–dependent proteins. The effect develops gradually because clotting factors already in circulation disappear according to their individual half-lives. This delay is one reason frequent, aggressive dose changes can overshoot the INR target.

The common c.-1639G>A variant is regulatory; it does not change the protein’s amino acid sequence. Its principal effect is on expression:

• G/G: usually more VKORC1 expression and lower sensitivity relative to A-allele carriers.
• G/A: intermediate expression and sensitivity.
• A/A: usually less expression, greater sensitivity, and a lower average dose requirement.

Some reports or older publications refer to VKORC1 1173C>T (rs9934438). It is often inherited with -1639G>A in many populations, so one marker may serve as a proxy for the other. The relationship and reporting convention can vary. Interpretation should use the exact variant, alleles, reference sequence, and laboratory explanation rather than an informal label such as “positive.”

VKORC1 is a pharmacodynamic gene because it changes response at the drug target. CYP2C9 is primarily pharmacokinetic because it changes how slowly or quickly S-warfarin is eliminated. A person with A/A at VKORC1 and reduced CYP2C9 function may be highly sensitive and slow to clear warfarin. Such a combination can produce a low requirement and a delayed response to dose changes.

CYP4F2 contributes through vitamin K oxidation. A common CYP4F2 variant can modestly increase dose requirements in some populations. The different roles of VKORC1, CYP2C9, and CYP4F2 explain why “warfarin sensitivity” is not a one-gene trait.

Who May Benefit and When Testing Helps Most

VKORC1 testing is most informative when a clinician must choose an initial warfarin dose before a stable INR pattern exists. Warfarin may be prescribed for atrial fibrillation, venous thromboembolism, selected cardiac procedures, or a mechanical heart valve. The indication determines whether warfarin is appropriate and what INR range is intended; genotype only informs dose sensitivity.

Testing may be useful when:

• warfarin is expected to continue long enough for improved initiation to matter;
• the result can return before or very early in treatment;
• CYP2C9 and other relevant markers are available simultaneously;
• the clinical team can use a validated pharmacogenetic algorithm;
• an INR overshoot would create particular concern;
• a prior unusually low dose suggests possible sensitivity, although a past stable dose may already be more informative.

Rapid turnaround matters. A result returned after several weeks of successful INR-guided titration may not change management. Preemptive testing can avoid that delay if the original clinical report is stored in an accessible health record and interpreted under current guidance.

Testing is not necessary for every person. Some anticoagulation services achieve safe initiation with clinical dosing protocols and close INR monitoring. Studies of genotype-guided dosing have produced different outcomes because they used different algorithms, ancestry groups, turnaround times, control strategies, and endpoints. The meaningful intervention is not merely ordering a test; it is returning an adequately comprehensive result soon enough to influence care.

Testing should not delay urgent anticoagulation or emergency treatment. It is also less helpful if the panel tests VKORC1 but omits CYP2C9 alleles relevant to the patient’s ancestry.

The choice between warfarin and a direct oral anticoagulant is a separate clinical decision. Some people have alternatives, while warfarin remains necessary or preferred in certain settings, including many mechanical-valve situations. Indication, kidney function, interactions, adherence, pregnancy considerations, cost, and specialist advice all matter. Genotype refines a warfarin plan; it does not choose the anticoagulant independently.

Sample Types, Methods, and Test Coverage

Testing usually uses DNA from blood or a cheek swab; some laboratories accept saliva. Because inherited DNA does not change, a reliable result ordinarily needs to be obtained only once.

Methods include targeted polymerase chain reaction assays, allele-specific genotyping, microarrays, and targeted sequencing. Routine warfarin sensitivity tests often use a focused assay for rs9923231. Multigene panels may add CYP2C9, CYP4F2, and selected markers in the CYP2C region.

Four report details deserve attention:

1. Exact variant: The report should identify rs9923231, c.-1639G>A, or another defined marker.
2. Allele orientation: Strand conventions can make allele letters look different across sources. Follow the laboratory’s validated interpretation rather than comparing letters without checking the reference sequence.
3. Panel scope: “Warfarin sensitivity” may describe a single VKORC1 marker, a limited CYP2C9/VKORC1 panel, or a more comprehensive assay. These do not provide equivalent information.
4. Clinical interpretation: The report should state the expected direction of effect and ideally connect it to a recognized dosing method.

A targeted common-variant assay is not full-gene sequencing. It generally does not search comprehensively for rare VKORC1 coding variants associated with hereditary warfarin resistance, structural changes, or uncertain variants. “No variant detected” means no tested variant was found, not that the entire gene was cleared of every relevant change.

Use an appropriately accredited clinical laboratory when results will guide prescribing. Direct-to-consumer raw data may contain rs9923231, but calls may be missing, incorrectly oriented, or unsupported by a clinical interpretation. A medical decision should rely on a clinical report or confirmatory test.

Turnaround may range from same day to several days or longer. Since usefulness declines as INR information accumulates, speed matters alongside analytical accuracy. Cost and coverage vary. An inexpensive isolated marker may offer poor value if the clinical team cannot use it in its dosing method.

How to Interpret VKORC1 Results

Most c.-1639G>A reports list one of three genotypes. The expected direction below is not a dosing instruction.

VKORC1 genotype	Typical sensitivity	Average dose direction	Main caution
G/G	Lower relative sensitivity	Often higher	Other genes and clinical factors may still produce a low requirement
G/A	Intermediate sensitivity	Often intermediate	Substantial overlap exists with both homozygous groups
A/A	Greater sensitivity	Often lower	Careful initiation and INR follow-up remain essential

The key concept is average. Two people with A/A can need different doses because their metabolism, age, body size, diet, illnesses, and medicines differ. G/G should never trigger an automatic high loading dose; it shifts only one part of the estimate.

Laboratories may use terms such as “high,” “moderate,” or “normal” sensitivity. These categories are not fully standardized. Some reports combine VKORC1 and CYP2C9 into an overall predicted range, while others list each gene separately. Read the methodology and gene-level findings instead of assuming identical labels reflect identical calculations.

Compare the result with observed response. An A/A result may help explain a steep INR rise on a small dose. If someone with A/A needs an unexpectedly high dose, clinicians should examine missed doses, schedule misunderstanding, vitamin K intake, enzyme-inducing medicines, malabsorption, and laboratory or timing issues before questioning the genotype.

Likewise, a person with G/G may need a low dose because of reduced CYP2C9 activity, advanced age, low body mass, liver dysfunction, acute illness, poor intake, or an interaction such as amiodarone. VKORC1 is one explanatory variable, not a verdict.

The genotype does not become more or less positive over time, although its interpretation may evolve as guidelines and algorithms improve. Retain the original report—including the tested variant and method—rather than only a simplified summary in a patient portal.

How Clinicians Turn a Result Into a Dose Estimate

VKORC1 is safest when used within a validated pharmacogenetic dosing algorithm rather than a one-gene lookup. Such algorithms combine genotype with clinical variables to estimate an initial or likely maintenance dose. Inputs may include:

• VKORC1 c.-1639G>A;
• CYP2C9 genotype and predicted metabolic activity;
• age, height, weight, or body surface area;
• ancestry-related variables when supported by the model;
• smoking status;
• amiodarone and selected enzyme inducers;
• target INR, indication, and other interacting medicines;
• CYP4F2 or additional markers in some algorithms.

The output is often milligrams per day or week. It is a starting estimate, not a permanent dose. Clinicians translate it into a practical tablet schedule, determine when to check INR, and adjust according to response. Whether temporary parenteral anticoagulation is required depends on the indication and clinical situation, not on VKORC1 genotype.

CYP2C9 is especially important because reduced-function alleles slow S-warfarin clearance. Their effect may unfold over several days. Escalating doses because the early INR seems low can later create excessive anticoagulation. Combining target sensitivity with clearance information is more coherent than interpreting either gene alone.

Coverage must fit ancestry. A panel limited to CYP2C9*2 and *3 captures important alleles in many people of European ancestry but may miss *5, *6, *8, and *11, which are more relevant in people with African ancestry. The CYP2C-region marker rs12777823 may also contribute in some patients of African ancestry. An accurate VKORC1 result cannot correct an incomplete CYP2C9 assessment.

FDA labeling and professional guidelines include genotype-informed approaches, including tables that cross VKORC1 and CYP2C9. These still require clinical judgment and INR monitoring. A table can mislead when CYP2C9 coverage is incomplete, major interactions are present, or the patient differs from the population on which the estimate was based.

The right question is not “What dose does A/A mean?” It is “Given this complete genotype and this patient’s clinical profile, what initial estimate and monitoring plan best reduce avoidable over- or under-anticoagulation?” A broader pharmacogenetic panel may include the required markers, but its warfarin coverage and algorithm must be verified.

INR Monitoring, Interactions, and Safety

INR monitoring converts an initial estimate into an individualized dose. Genotype is fixed; INR measures the anticoagulant effect occurring now.

INR is checked frequently during initiation and after dose changes. Testing may become less frequent after a stable dose is established, then increase after a new medicine, acute illness, hospitalization, major dietary change, missed doses, or an unexpected result. The care team should define who receives each INR and who is responsible for changing the dose.

Warfarin has many interactions. Some antibiotics, antifungals, and amiodarone can increase effect in certain circumstances. Enzyme inducers can reduce it. Antiplatelet drugs and nonsteroidal anti-inflammatory drugs may increase bleeding even without a large INR change. Alcohol patterns, supplements, and intermittent over-the-counter products also matter. Patients should check with the anticoagulation team before starting, stopping, or substantially changing any medicine or supplement.

Vitamin K intake should generally be consistent, not eliminated. Leafy greens and other nutritious foods can remain in the diet. Abrupt changes in intake can destabilize INR, as can vomiting, diarrhea, poor nutrition, or acute illness.

Seek urgent assessment for vomiting blood, black or bloody stools, coughing blood, uncontrolled bleeding, severe or persistent headache, sudden weakness, confusion, fainting, or a significant fall or head injury. Sudden shortness of breath, chest pain, one-sided weakness, speech difficulty, or a swollen painful leg may indicate a clot and also require urgent care. Do not wait for a genetic interpretation in an emergency.

For a missed dose, follow the anticoagulation service’s instructions rather than doubling automatically. Written calendars and pill organizers can prevent errors when the daily amount varies across the week.

Warfarin can harm a developing fetus in many circumstances. Pregnancy or pregnancy planning requires specialist management. A favorable genotype does not make warfarin broadly safe during pregnancy.

Limitations, Rare Resistance, and Next Steps

VKORC1 -1639G>A explains meaningful dose variability but not all of it. Allele frequencies differ across ancestry groups, and a model performs best when relevant genetic and clinical variables were represented during development. An algorithm may be less accurate if it uses incomplete allele coverage or oversimplified ancestry categories.

Trials of genotype-guided warfarin dosing have not produced uniform results. Differences in genotyping scope, turnaround time, population, comparator, and outcome help explain the variation. A rapid, ancestry-appropriate test integrated into a capable anticoagulation service is not equivalent to an isolated delayed result.

Rare VKORC1 coding variants can cause pharmacodynamic warfarin resistance, sometimes requiring unusually high doses to inhibit the target. Routine -1639 testing usually does not detect them. True hereditary resistance is uncommon. Before specialized sequencing, clinicians generally investigate missed doses, high or inconsistent vitamin K intake, enzyme-inducing medicines, malabsorption, laboratory error, or dose changes made before steady state.

An inconclusive result can arise from poor sample quality, assay interference, or a laboratory limitation. Recollection or a different method may be appropriate. Otherwise, repeating the identical common-variant test is rarely useful because the inherited genotype does not change.

After receiving a report:

1. Confirm the exact variant and genotype.
2. Determine whether CYP2C9, CYP4F2, and ancestry-relevant markers were tested.
3. Give the complete report to the prescriber or anticoagulation clinic before initiation when possible.
4. Use a validated dosing method rather than translating the genotype informally.
5. Establish the INR target, test schedule, interaction plan, missed-dose instructions, and emergency guidance.
6. Store the original report in the medical record for future use.

The final care plan should state the initial estimate, first INR date, responsible clinician, dietary and medication precautions, and urgent warning signs. Genetic information improves safety only when it is connected to those operational steps.

The central interpretation is simple: the VKORC1 -1639 A allele generally predicts greater sensitivity and a lower average warfarin requirement. Applying it safely is more demanding. Dose must come from the combined genetic and clinical picture and then be tested against the patient’s actual INR response.

References

• Clinical Pharmacogenetics Implementation Consortium Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update — 2017, clinical practice guideline.
• Warfarin Therapy and VKORC1 and CYP Genotype — 2018, continuously updated medical genetics summary.
• Comparative Performance of Pharmacogenetics-Based Warfarin Dosing Algorithms — 2024, comparative clinical study.
• Application of Rapid Genotyping of Warfarin Individualized Pharmacogenetic Variants in Warfarin Therapy — 2024, analytical and clinical research study.
• The Impact of CYP2C9, VKORC1, and CYP4F2 Polymorphisms on Warfarin Dose Requirement in Saudi Patients — 2025, pharmacogenetic cohort study.
• Warfarin Sensitivity Genotyping Test Fact Sheet — 2025, clinical laboratory guidance.

Disclaimer

This article is for general educational purposes and is not a substitute for individualized medical advice, anticoagulation management, genetic counseling, or emergency care. Do not start, stop, or change warfarin based on a genetic result without the prescribing clinician, and continue all scheduled INR testing. Seek urgent care for serious bleeding, head injury while anticoagulated, or symptoms of a possible blood clot.